Clicky

Resverlogix Corp.(RVX)

Description: Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.


Keywords: Medicine Biotechnology Disease Diabetes Clinic Clinical Trial Alzheimer's Disease Cardiovascular Disease Beta Kidney Disease Chronic Kidney Disease Chronic Condition Diabetes Mellitus IPO Chronic Kidney Peripheral Arterial Disease Peripheral Artery Disease Paroxysmal Nocturnal Hemoglobinuria High Density Lipoprotein Bromodomain High Risk Cardiovascular Disease Rvx 208

Home Page: www.resverlogix.com

RVX Technical Analysis

4820 Richard Road SW
Calgary, AB T3E 6L1
Canada
Phone: 403 254 9252


Officers

Name Title
Mr. Donald J. McCaffrey Co-Founder, Chairman, Pres, CEO & Sec.
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV Chief Financial Officer
Dr. Ewelina Kulikowski Ph.D. Chief Scientific Officer
Dr. Jan O. Johansson M.D., Ph.D. Sr. VP of Medical Affairs
Dr. Michael Sweeney M.D. Sr. VP of Clinical Devel.
Sarah Zapotichny Director of Investor Relations & Corp. Communications

Exchange: TO

Country: CA

Currency: Canadian Dollar (C$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: April
Full Time Employees: 22
Back to stocks